|
Characteristics
|
n = 159 (%)
|
|
Stage at diagnosis
|
|
I
|
17 (11)
|
|
II
|
50 (31)
|
|
III
|
32 (20)
|
|
IV
|
31 (20)
|
|
Unknown
|
28 (17)
|
|
Subtype
|
|
HR+ HER2-
|
108 (68)
|
|
HR+ HER2+
|
20 (13)
|
|
HR- HER2+
|
9 (6)
|
|
HR- HER2-
|
14 (9)
|
|
Unknown
|
8 (5)
|
|
Perioperative chemotherapy
|
|
Yes
|
61 (38)
|
|
Anthracycline regimen
|
11 (7)
|
|
Anthracycline + taxane regimen
|
26 (16)
|
|
Other regimens
|
24 (15)
|
|
No
|
97 (61)
|
|
Unknown
|
1 (1)
|
|
Adjuvant endocrine therapy
|
|
Aromatase inhibitor
|
39 (25)
|
|
Tamoxifen
|
29 (19)
|
|
Ovarian function suppression
|
22 (14)
|
|
None
|
22 (14)
|
|
Unknown
|
1 (1)
|
|
Prior treatment with zoledronic acid
|
|
Yes
|
39 (25)
|
|
No
|
92 (60)
|
|
Unknown
|
23 (15)
|
|
Number of denosumab doses
|
median 18 (range: 1–79)
|
|
More than 45 doses of denosumab
|
15 (9)
|
